Abstract
Sialor, a sialogogue, was studied in a double-blind crossover trial in patients with autoimmune exocrinopathy (Sjögren's syndrome). Sialor appears to frequently alleviate the symptoms of xerostomia and increase salivary flow rate, and it is rarely associated with side effects. Sialor is useful in management of xerostomia in patients with Sjögren's syndrome and may also be of value in the treatment of xerophthalmia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have